California-based obesity-focused clinical-stage pharma Aardvark Therapeutics saw its shares tumble nearly 26% to $4.99, after it announced that the US Food and Drug Administration (FDA) has placed a ...

Swedish neuroscience specialist BioArctic (Nasdaq Stockholm: BIOA B) said partner Eisai expects Alzheimer’s disease therapy ...

Bristol Myers Squibb’s Eliquis (apixaban) is on course for one of the largest single-asset revenue collapses in ...

Vetter is celebrating the start of construction on its new site in Saarlouis with a traditional ground-breaking ceremony today.

US regulator the Food and Drug Administration has granted accelerated approval to Beqalzi (sonrotoclax), giving BeOne ...

Italian drugmaker Recordati reported first-quarter 2026 revenue of 713 million euros ($775 million) on Tuesday, up 5% year-on ...

Japan’s largest drugmaker Takeda today announced financial results for the fiscal year 2025 (period ended March 31, 2026).

US biotech Rigel Pharmaceuticals is betting heavily on the newly-approved breast cancer therapy Veppanu (vepdegestrant), ...

Spanish drugmaker Almirall has reported first-quarter 2026 results in line with expectations, driven by continued strong ...

Danish CNS specialist Lundbeck reported that total revenue for the first quarter of 2026 grew by +21% constant exchange rate ...

The global DNA synthesis market is projected to grow from $5.7 billion in 2025 to $30.4 billion by 2035, according to a new ...

UK pharma major GSK has entered into an exclusive strategic collaboration with Sino Biopharmaceutical (SBP Group), through ...